Form 4: VolitionRx Chief Medical Officer's Stock Transaction for Tax Withholding

VolitionRx's Chief Medical Officer, Andrew Retter, had 4,401 shares of common stock withheld by the company to cover tax obligations related to the settlement of restricted stock units.

Summary

• Andrew Retter, Chief Medical Officer of VolitionRx Ltd (VNRX), reported a transaction on July 1, 2025.
• 4,401 shares of common stock were disposed of to the issuer (VolitionRx) at a price of $0.7679 per share.
• This disposition was solely to satisfy tax withholding obligations upon the settlement of 9,365 restricted stock units (RSUs).
• The RSUs were awarded in lieu of cash compensation.
• No shares were sold by Andrew Retter or VolitionRx in this transaction.
• Following this transaction, Andrew Retter beneficially owns 137,774 shares of VolitionRx common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine compliance filing for an insider transaction related to equity compensation and tax withholding. It does not indicate positive or negative operational performance or strategic shifts.

Positives

• The transaction was a non-sale disposition for tax withholding, indicating the settlement of previously awarded restricted stock units.
• The restricted stock units were awarded in lieu of cash compensation, which can be a positive for company cash flow management.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction related to equity compensation.

Management Comments

• Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,365 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person.
• No shares were sold by the reporting person or VolitionRx in such transaction.

Industry Context

This is a routine insider transaction filing (Form 4) common across all publicly traded companies when executives' equity compensation (like restricted stock units) vests. It reflects standard compensation practices and tax compliance rather than a specific industry trend or competitive action.

Comparison to Industry Standards

• The transaction, involving the withholding of shares for tax obligations upon RSU vesting, is a standard practice for equity compensation in publicly traded companies across various industries.
• It aligns with typical compensation structures where restricted stock units are granted and then settled, with a portion of shares often withheld to cover statutory tax liabilities.
• No specific comparable companies or projects are relevant as this is a compliance filing for a routine compensation event.

Stakeholder Impact

• Shareholders: The transaction is a routine tax withholding event for executive compensation and does not directly impact shareholder value or ownership structure beyond the standard dilution from equity compensation plans.
• Employees: Reflects the company's use of restricted stock units as a form of compensation, which can be a positive for employee retention and alignment of interests.

Key Dates

Keywords

VolitionRx, VNRX, Form 4, SEC filing, insider transaction, Andrew Retter, Chief Medical Officer, restricted stock units, tax withholding, equity compensation